Yahoo: What’s Up Doc? Molluscum contagiosum causes no symptoms, but can cause itching Q: My neighbor’s son was just diagnosed with a molluscum contagiosum rash. Is it safe for my neighbor's son to play with my son?

Understanding the Context

A: Molluscum contagiosum (MC) is caused by a virus in the Poxviridae ... What’s Up Doc? Molluscum contagiosum causes no symptoms, but can cause itching Molluscum contagiosum (MC), a viral skin infection caused by the poxvirus, often presents challenges in treatment due to limited therapeutic options. However, a potential breakthrough has emerged with ...

Key Insights

Topical cantharidin (Ycanth) was approved as the first treatment specifically for molluscum contagiosum, the FDA announced. Molluscum contagiosum is a viral skin infection that affects as many as 6 ... Molluscum contagiosum is a prevalent viral skin infection, particularly in children, that presents as small, firm, flesh-coloured papules. Although the condition is typically self‐limiting, its ... A novel nitric oxide-releasing gel led to significantly more patients achieving complete clearance of their lesions from molluscum contagiosum infections compared with a vehicle control, and was safe ...

Final Thoughts

Business Wire: U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum Yahoo Finance: Alphyn Completes Enrollment in Phase 2 Trial of Topical Therapy for Molluscum Contagiosum Alphyn Completes Enrollment in Phase 2 Trial of Topical Therapy for Molluscum Contagiosum Nasdaq: Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals Pelthos is set to launch ZELSUVMI™, the first and only home-administered prescription treatment for Molluscum contagiosum, addressing a significant unmet need. The successful merger has raised $50.1 ... Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals